Search clinical trials for: Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection

Total 682 results

Virginia Commonwealth University
National Cancer Institute (NCI)

Completed

SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx

Solid Tumor

United States
Bio-Thera Solutions

Active, not recruiting

Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients

Plaque Psoriasis

China
Peking University Cancer Hospital & Institute

Recruiting

Study to Evaluate OrienX010 in Combination With JS001 in the Treatment of Stage IV (M1c) Liver Metastasis From Melanoma

Melanoma

China
Peking University Cancer Hospital & Institute

Active, not recruiting

Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Melanoma

Melanoma

China
Xijing Hospital

Not yet recruiting

RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer

Breast Cancer | HER2-positive Breast Cancer
Shanghai Henlius Biotech

Active, not recruiting

A Randomized, Single Intravenous Dose, Parallel Phase I Clinical Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX05 Vs. Erbitux® (Cetuximab) in Healthy Adult Male Chinese Subjects

EGFR Overexpression

China
Fudan University

Recruiting

PD-1 Inhibitor and Nab-paclitaxel and Bevacizumab in CUP

Cancer of Unknown Primary

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors

Bone Metastases

China
National Cancer Institute (NCI)

Terminated

Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer

Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Qilu Hospital of Shandong University
Shandong Provincial Hospital; Qingdao Municipal Hospital; China-Japan Friendship... and other collaborators

Recruiting

Bevacizumab in Patients With Severe Covid-19 (BEST)

COVID-19 Pneumonia

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC

Nasopharyngeal Carcinoma | Head and Neck Squamous Cell Carcinom

China
Jasper Therapeutics, Inc.

Recruiting

JSP191 Antibody Targeting Conditioning in SCID Patients

SCID

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical Cancer

Uterine Cervical Cancer

China
Shanghai Henlius Biotech

Completed

Evaluate the Safety and Efficacy of HLX04-O in Subjects With wAMD

Age Related Macular Degeneration

China
ThromboGenics

Completed

A Study to Evaluate the Safety and Efficacy of THR-317 for the Treatment of Diabetic Macular Oedema (DME)

Diabetic Retinopathy | Macular Edema

Czechia, Slovakia, Hungary
Qilu Pharmaceutical Co., Ltd.

Completed

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.

Breast Cancer

China
BZL Biologics

Completed

Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2

Prostatic Neoplasms

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours

Lymphoma | Cervical Cancer | Malignant Mesothelioma | Advanced Solid Tumours | Non-Small-Cell Lung Cancer

China
Sun Yat-sen University
Shanghai Junshi Bioscience Co., Ltd.; CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma

Esophageal Small Cell Carcinoma

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Comparing of the PK, PD, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults

Healthy

China
Shandong Boan Biotechnology Co., Ltd

Completed

Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male Subjects

Metastatic Colorectal Cancer | Non Small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer Recurrent

China
Waterstone Hanxbio Pty Ltd

Recruiting

Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma

Relapsed/Refractory Lymphoma

China
Guangzhou Gloria Biosciences Co., Ltd.

Completed

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Zhejiang Teruisi Pharmaceutical Inc.

Recruiting

A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.

CD20-positive B-cell Non-Hodgkin Lymphoma

China
Case Comprehensive Cancer Center

Completed

Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy

Prostate Cancer

United States
Shanghai Henlius Biotech

Suspended

Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients With mCRC

Colorectal Cancer Metastatic

China
Peking University Cancer Hospital & Institute

Not yet recruiting

Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis

Melanoma Stage IV
Dragonboat Biopharmaceutical Company Limited

Unknown

Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors

Advanced Tumors

China
Shanghai Zhangjiang Biotechnology Limited Company

Completed

Safety and Efficacy Study of Omalizumab to Treat Allergic Asthma (AA007)

Allergic Asthma

China
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma

Eosinophilic Asthma

United States, Australia, Belgium, Chile, Colombia, Denmark, Hungary, Israel, Malaysia, New Zealand, Philippines, Poland, Russian Federation, South Africa, Sweden, Thailand, Argentina, Brazil, Canada, France, Mexico, Netherlands, Ge... and more
Shanghai Henlius Biotech

Completed

Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor

Adult Solid Tumor

China
CINJRegulatory
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Terminated

High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Not yet recruiting

A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

Acute Gout
Jasper Therapeutics, Inc.

Recruiting

JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation

MYELODYSPLASTIC SYNDROME; MDS | ACUTE MYELOID LEUKEMIA; AML

United States
Peking University
Shanghai Junshi Bioscience Co., Ltd.

Completed

Study of JS001 in Patients With Advanced Neuroendocrine Tumors

Neuroendocrine Tumors

China
Bio-Thera Solutions

Unknown

A Clinical Trial of BAT8001 on Safety, Tolerability and Pharmacokinetics for Patients

HER2-Positive Solid Tumors

China
Humanigen, Inc.

Terminated

Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

Eosinophilic Asthma

United States, Australia, Belgium, Chile, Colombia, Czechia, Denmark, Hungary, Israel, Malaysia, New Zealand, Philippines, Poland, Russian Federation, South Africa, Sweden, Thailand
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma

Eosinophilic Asthma

United States, Argentina, Brazil, Canada, France, Mexico, Germany, Greece, Korea, Republic of, Peru, Romania, Russian Federation, Slovakia, Taiwan, Ukraine
Luye Pharma Group Ltd.

Recruiting

Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors

Bone Metastases From Solid Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Comparative Clinical Trial to Evaluate Bioequivalency and Safety of Monoclonal Antibody Injection and Adalimumab in Chinese Healthy Volunteers

Healthy
National Institute of Allergy and Infectious Diseases...
GlaxoSmithKline; Rho Federal Systems Division, Inc.; Inner-City Asthma Consortium

Completed

A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children (MUPPITS-2)

Asthma

United States
Sanofi

Completed

A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy Adults

Paroxysmal Nocturnal Hemoglobinuria

United States
University of Athens

Completed

Anakinra in Hidradenitis Suppurativa

Hidradenitis Suppurativa

Greece
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma

Eosinophilic Asthma

United States, Belgium, Colombia, Hungary, Israel, Poland, Sweden, Argentina, Brazil, Canada, France, Mexico, Netherlands
Bio-Thera Solutions

Not yet recruiting

BAT1308 Combined With Platinum-Based Chemotherapy± Bevacizumab For PDL1-Positive (CPS ≥1) Cervical Cancer

Cervical Cancer

China
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Prostate Cancer

United States
Bio-Thera Solutions

Terminated

Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumour Patients

Advanced Solid Tumour

Australia
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma

Advanced Melanoma | Kidney Cancer Stage Iv

China

Search clinical trials for: Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations